A few clinical trials involving Enasidenib are still in the planning stages and are not yet actively recruiting (ClinicalTrials.gov NCT03728335, NCT03720366), and one phase 1 trial investigating pan-inhibitor AG-881 (ClinicalTrials.gov NCT02492737) in advanced hematologic malignancies with either IDH1 or IDH2 mutations concluded in 2018, but no trial results have been released. This evidence concerns the gene IDH2 and hematologic disorder.